Interestingly, the anti-SLAMF7 antibody-elotuzumab has been approved for use by Food and Drug Administration (FDA), and enhances natural killer cell activation and cancer cell killing through interleukin-2 and TNF-α pathways, significantly improving progression-free survival of multiple myeloma [32–34]. Here, SLAMF7 is linked to plasma cell myeloma.